Cargando…
(177)Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
SIMPLE SUMMARY: Neuroendocrine Tumors are rare cancers with limited therapeutic options. Functioning NETs could produce bioactive peptides leading to a specific syndrome that impacts on patients’ quality of life and also on survival—F-NETs patients who are refractory to SSA respond to 177LU-PRRT wit...
Autores principales: | Bongiovanni, Alberto, Nicolini, Silvia, Ibrahim, Toni, Foca, Flavia, Sansovini, Maddalena, Di Paolo, Arianna, Grassi, Ilaria, Liverani, Chiara, Calabrese, Chiara, Ranallo, Nicoletta, Matteucci, Federica, Paganelli, Giovanni, Severi, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776442/ https://www.ncbi.nlm.nih.gov/pubmed/36551507 http://dx.doi.org/10.3390/cancers14246022 |
Ejemplares similares
-
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017) -
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
por: Liverani, Chiara, et al.
Publicado: (2023) -
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017) -
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021) -
Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)